The company's first years were difficult but in the very early 1990s, Jean-Pierre Delwart,[3] economist from Brussels University, boarded the ship and put Eurogentec in a favorable current.

[1] In 1996, it became a contract research organization (CRO) for the biopharmaceutical sector and entered into collaboration with SmithKline Beecham biologicals (Rixensart, Belgium) for the production of recombinant proteins for phase I, II and III clinical trials.

[1] In 1999, Eurogentec acquired Oswel Research Product Ltd.[4] a biotechnology company based in Southampton, Great Britain and specialized in the synthesis of chemically modified and complex oligonucleotides and their analogues (DNA, RNA, PNA).

[13] 2007: In order to fully meet the Oligonucleotide in vitro diagnostics stringent manufacturing requirements, Eurogentec expanded its current GMP facility in Liège.

Eurogentec has developed three interrelated business units, Life Science Research Products and Services, In Vitro Diagnostics Manufacturing Solutions, and GMP Biomanufacturing.